primary endpoints

Related by string. primary endpoint * pri mary . PRIMARY . Primary : Primary Care Trust . Primary Care Trusts . Primary Leaving Examinations / Endpoint . Endpoints . EndPoint : Secondary endpoints include . primary efficacy endpoint . secondary efficacy endpoints * Meets Primary Endpoint . Meet Primary Endpoint . Achieves Primary Endpoint . specified primary endpoint *

Related by context. All words. (Click for frequent words.) 84 primary efficacy endpoints 83 primary endpoint 80 primary efficacy endpoint 76 secondary endpoints 76 secondary efficacy endpoints 74 secondary endpoint 71 efficacy endpoints 64 non inferiority 64 demonstrated statistically significant 64 efficacy endpoint 63 Secondary endpoints 63 prospectively defined 62 prespecified 62 clinical endpoints 61 achieved statistical significance 61 desvenlafaxine succinate 61 Primary endpoints 61 noninferiority 60 composite endpoint 60 Secondary endpoints included 60 secondary efficacy endpoint 60 elagolix 58 evaluable 58 timepoint 58 viral kinetic 58 ACTEMRA 58 clinically meaningful 58 achieve statistical significance 57 statistically significant improvement 57 statistical significance 57 TRITON TIMI 57 mg BID 57 pharmacodynamic 57 phase IIa 57 prespecified criteria 57 tolerability 57 dosage regimens 57 Secondary efficacy endpoints 57 undetectable HCV RNA 56 HCV RESPOND 2 56 lipid parameters 56 active comparator 56 evaluable patients 56 prospective multicenter randomized 56 placebo 56 alvimopan 56 SVR# 56 ACR# response 56 morphometric vertebral fractures 56 tapentadol ER 56 pharmacokinetics PK 56 mg dose 55 viral kinetics 55 rALLy trial 55 diabetic neuropathic pain 55 MAP# 55 REYATAZ r 55 bosentan 55 undetectable HBV DNA 55 placebo controlled clinical trials 55 dosing regimens 55 dose regimens 55 statistically significant reduction 55 teriflunomide 55 ACTEMRA TM 55 Phase 2b study 55 patients evaluable 55 EURIDIS 55 endpoints 55 VIRAMUNE XR 55 evaluating REVLIMID 55 CIMZIA TM certolizumab pegol 55 ATACAND 55 #mg BID [001] 55 ruboxistaurin 55 Phase IIb clinical 55 1mg dose 55 mg QD 54 rolofylline 54 GOUT 54 oxycodone CR 54 placebo controlled 54 HbA1c levels 54 ACE inhibitor ramipril 54 bicifadine 54 pain palliation 54 ABC/3TC 54 RE LY ® 54 rapid virologic response 54 nab paclitaxel 54 Secondary endpoints include 54 LEVADEX 54 apremilast 54 dose cohorts 54 ribavirin RBV 54 #mg QD [001] 54 nonresponders 54 analgesic efficacy 54 QNEXA 54 Lupuzor ™ 54 pharmacokinetic PK 54 randomized placebo controlled 54 Neuropsychiatric Inventory NPI 54 PEG Intron 54 ancrod 54 Proellex TM 54 mcg BID 54 posaconazole 54 MEND CABG II 54 abacavir lamivudine 54 sustained virologic response 54 oral rivaroxaban 54 BRIM3 54 virological response 54 PASI scores 54 headache nasopharyngitis 54 vismodegib 54 MIST II 54 HBeAg positive patients 54 subanalysis 54 angiographic outcomes 54 elotuzumab 54 tolvaptan 54 placebo controlled clinical 53 CCyR 53 sUA 53 iniparib 53 statistically significant 53 endoscopic remission 53 catheter occlusion 53 teduglutide 53 dosing cohort 53 trospium 53 HBeAg negative patients 53 multiple ascending dose 53 mg doses 53 dimebon 53 dose limiting toxicities 53 NLX P# 53 chlorambucil 53 lopinavir r 53 null responders 53 fosbretabulin 53 insulin detemir 53 Psoriasis Area 53 vidofludimus 53 dosing cohorts 53 Azixa 53 BENICAR 53 candesartan cilexetil 53 glufosfamide 53 oral FTY# 53 pharmacokinetic PK profile 53 PRE SURGE 53 plus dexamethasone 53 tolerability profile 53 arzoxifene 53 statistical significance p 53 Phase IIa clinical 53 administered subcutaneously 53 virologic response 53 ENDEAVOR II 53 ACR# [002] 53 prospective randomized controlled 53 DSMB 53 KRN# 53 LEXIVA r 53 trials RCTs 53 PREZISTA r 53 pivotal Phase III 53 plus methotrexate 53 Montgomery Asberg Depression 53 midstage study 53 tanespimycin 53 colesevelam HCl 53 Solid Tumors criteria 53 REMINYL ® 53 spontaneous bowel movements 53 PRIMO CABG2 53 Phase IIa trial 53 eszopiclone 53 demonstrated clinically meaningful 53 #.#/#.# mmHg [001] 53 GAMMAGARD 52 Phase 2a clinical 52 prespecified secondary 52 retinal thickness 52 RoACTEMRA 52 HCV SPRINT 52 clinically meaningful improvements 52 complete cytogenetic 52 Crohn Disease Activity 52 Pegasys ® 52 mg/m2 dose 52 timepoints 52 treatment emergent adverse 52 phase IIb study 52 unblinded 52 Phase 2a 52 Phase IIB 52 AeroLEF 52 plus ribavirin 52 placebo controlled randomized 52 μg dose 52 Phase 2b clinical 52 postdose 52 BENICAR HCT 52 SPIRIT FIRST 52 Phase IIa 52 mucosal healing 52 Phase 2b 52 Endpoints 52 #mg dose [002] 52 pharmacodynamic PD 52 free survival PFS 52 varespladib 52 peg interferon 52 INCB# [001] 52 pramlintide metreleptin combination 52 antiviral efficacy 52 lopinavir r arm 52 ANCHOR trial 52 LIALDA 52 LEXIVA 52 peg IFN 52 certolizumab 52 Androxal TM 52 CHAMPION PLATFORM 52 NSABP C 52 mcg kg 52 phase IIb clinical 52 pharmacokinetic 52 #mg/day [001] 52 ascending doses 52 DSM IV criteria 52 PRIMO CABG 52 CIMZIA TM 52 progression TTP 52 oral ridaforolimus 52 pertuzumab 52 achieved ACR# 52 #μg [002] 52 metabolic parameters 52 mcg QD 52 interferon ribavirin 52 XIENCE V PROMUS Stent 52 clinically meaningful improvement 52 #mg QD [002] 52 virologic failure 52 HBeAg seroconversion 52 MoxDuo TM IR 52 efficacy 52 cytogenetic response 52 Dacogen injection 52 #mg BID [003] 52 Phase 1b 52 TMC# C# 52 Contrave# 52 rosuvastatin #mg 52 Phase III placebo controlled 52 Phase 2a trial 52 statistically significant superiority 52 pharmacokinetic profiles 52 Phase IIb trials 52 #mg/m# [002] 52 clazosentan 52 phase 2a 52 p = #.# [002] 52 NATRECOR R 52 STRIDE PD 52 NATRECOR ® 52 pegylated interferon alfa 2a 52 complete cytogenetic response 52 evaluable subjects 52 Rating Scale MADRS 52 randomized controlled 52 tipranavir 51 pharmacokinetic PK study 51 randomized Phase 2b 51 BRIM2 51 tumor progression TTP 51 placebo controlled Phase 51 sumatriptan naproxen sodium 51 CANCIDAS 51 genotypic resistance 51 primary hypercholesterolemia 51 MERLIN TIMI 51 ARCOXIA 51 ACR# ACR# 51 valopicitabine 51 preclinical pharmacokinetic 51 telbivudine 51 rindopepimut 51 RG# [001] 51 #mg/day [002] 51 edoxaban 51 phase Ib 51 achieved PASI 51 trastuzumab emtansine T DM1 51 ticagrelor 51 Thrombolysis 51 neurologic progression 51 Phase IIIb clinical 51 FOLFOX4 51 randomized #:# 51 dose escalation phase 51 mcg albinterferon alfa 2b 51 octreotide LAR 51 monotherapy 51 daclizumab 51 COMFORT II 51 incidence ≥ 51 Ostarine 51 prospective randomized multicenter 51 mITT population 51 docetaxel Taxotere ® 51 Phase III clinical 51 R# #mg BID 51 ALVESCO 51 placebo controlled trials 51 TAXUS ATLAS 51 CR nPR 51 Negative Syndrome 51 placebo controlled Phase III 51 peginterferon 51 TLUS 51 Response Evaluation Criteria 51 plus COPEGUS 51 ORMD 51 Phase #b/#a clinical 51 log# IU mL 51 LymphoStat B 51 pivotal Phase 51 lixisenatide 51 Ereska 51 MEND CABG 51 phase IIb 51 phase IIIb 51 enoximone 51 APPRAISE 51 A1c levels 51 Amigal 51 multicenter randomized placebo controlled 51 INCB# [003] 51 pramlintide 51 CIMZIA ™ 51 RECIST Response Evaluation Criteria 51 sustained virological response 51 Corlux 51 limiting toxicity 51 metastatic castration resistant 51 4mg/kg 51 multicenter Phase III 51 cobicistat 51 TELCYTA 51 baminercept 51 Phase III pivotal 51 deforolimus 51 randomized 51 mg kg BID 51 nonfatal MI 51 Phase IIb 51 PRX # 51 comparator arm 51 Tarceva TM 51 Phase Ib clinical 51 zonisamide SR 51 recurrent glioblastoma multiforme 51 PEGylated interferon beta 1a 51 riociguat 51 GSK# [001] 51 Forodesine HCl 51 Traficet EN 51 FOLPI 51 tolerated dose MTD 51 PEG Interferon lambda 51 cardiovascular morbidity 51 Phase IIb trial 51 HGS ETR1 51 Pivotal Phase III 51 PREZISTA r arm 51 cethromycin 51 ibandronate 51 COMBIVIR 51 relapsing multiple sclerosis 51 MADRS score 51 Pharmacokinetic parameters 51 aclidinium 51 randomized multicenter trial 51 binary restenosis 51 AEGR 51 AGILECT R 51 VELCADE melphalan 51 achieve sustained virologic 51 aflibercept 51 mg kg dose 51 mg RDEA# 51 eplerenone 51 UPLYSO 51 predefined criteria 51 ZOLINZA 51 Capesaris 51 clinically relevant 51 Phase 2b trial 51 pharmacodynamic effects 51 multicenter Phase 51 ADAS cog 51 QD dosing 51 virologic 51 SPIRIT III 51 reach statistical significance 51 randomized double 51 XIENCE V demonstrated 51 efficacy tolerability 51 Adalimumab 51 pharmacokinetic parameters 51 NYHA Class II 51 adjunctive placebo 51 Pegasys plus Copegus 51 low dose cytarabine 51 Zenvia 51 #mg BID [002] 51 phase IIa clinical 51 events AEs 51 Score TOS 51 lacosamide 50 HbA1c 50 surrogate endpoint 50 NO# [002] 50 FOLFIRI 50 tecarfarin 50 double blind placebo 50 mesalamine granules 50 Ocrelizumab 50 rotigotine 50 adefovir 50 APTIVUS r 50 specified primary endpoint 50 ischemic cardiomyopathy 50 pharmacokinetic characteristics 50 ataluren 50 DAS# CRP 50 randomized multicenter 50 pharmacokinetic profile 50 irbesartan 50 Index CDAI 50 dose titration 50 maximally tolerated dose 50 alpha 2a 50 fasting plasma glucose 50 iclaprim 50 ENDEAVOR III 50 custirsen 50 GFT# 50 alicaforsen enema 50 Phase Ib 50 symptomatic VTE 50 AzaSite Plus 50 TOLAMBA 50 ACCORD Lipid 50 Dapagliflozin 50 PANSS 50 prucalopride 50 unresectable HCC 50 inhibitor RG# 50 Virulizin ® 50 Study GL# 50 RSD# oral 50 adalimumab 50 opioid induced bowel dysfunction 50 ToGA 50 undetectable viral load 50 entecavir 50 telcagepant 50 APEX AMI trial 50 dose regimen 50 placebo p 50 PFO migraine 50 nonrandomized 50 SIMPADICO 50 vandetanib 50 remission CR 50 imatinib therapy 50 TroVax 50 double blinded placebo 50 MADRS 50 mcg dose 50 SPIRIVA HandiHaler 50 melphalan prednisone 50 dacarbazine chemotherapy 50 huC# DM4 50 rilpivirine 50 EDEMA3 50 PEGylated anti 50 multicenter placebo controlled 50 tolerability profiles 50 Phase Ib study 50 EchoCRT 50 EVEREST II 50 SCH # 50 serum HCV RNA 50 RESIST studies 50 Solid Tumors RECIST 50 Board DSMB 50 Scale EDSS 50 multicentre randomized 50 Virologic 50 IIIa inhibitor 50 incontinence episodes 50 attain statistical significance 50 lubiprostone 50 Multiple Ascending Dose 50 TEAEs 50 Montgomery Åsberg Depression 50 EFAPROXYN 50 avosentan 50 docetaxel chemotherapy 50 liver histology 50 oral prodrug 50 radiographic progression 50 LPV r 50 Doxil ® 50 ritonavir boosted 50 SYMMETRY trial 50 PS# [001] 50 IR prednisone 50 AZILECT R 50 tocilizumab 50 commercialization milestones 50 HORIZONS AMI trial 50 Phenoptin 50 Golimumab 50 cystinosis patients 50 ATTAIN 50 celgosivir 50 oral deforolimus 50 denufosol 50 Pharmacokinetic 50 interferon gamma 1b 50 mg ustekinumab 50 canakinumab 50 TIMI 50 randomized #:#:# 50 RECIST criteria 50 prospective randomized placebo 50 BoNTA 50 NYHA class 50 placebo controlled studies 50 lomitapide 50 CRp 50 KRAS mutations occur 50 safinamide 50 ritonavir boosting 50 Tasimelteon 50 Phase 2b kidney transplant 50 dose proportionality 50 CSBM 50 randomized Phase III 50 brivaracetam 50 EDEMA3 trial 50 DASISION 50 nucleoside naive patients 50 plasma HCV RNA 50 dyskinesia PD LID 50 Welchol 50 Sorafenib HCC Assessment 50 salmeterol fluticasone 50 solifenacin 50 abdominal pain abdominal discomfort 50 NYHA functional class 50 ASCEND HF 50 prior chemotherapy regimens 49 methacholine challenge 49 clevidipine 49 peginesatide 49 chronic angina 49 Expanded Disability Status 49 DP b# 49 confirmatory Phase 3 49 lymphoma CTCL 49 GERD symptom 49 Aflibercept 49 linaclotide treated 49 oblimersen 49 ABSORB trial 49 COPEGUS 49 INCB# [002] 49 peginterferon alfa 2b 49 clinical pharmacology studies 49 dirucotide 49 VA# [002] 49 mRCC 49 APTIVUS 49 plus prednisone 49 virologic response EVR 49 DAPT 49 oral dosing 49 gout flares 49 subgroup analyzes 49 telaprevir dosing 49 febuxostat 49 reactogenicity 49 tezampanel 49 systemically administered 49 RE SURGE 49 adenoma recurrence 49 Tiotropium 49 forodesine 49 velafermin 49 oral methylnaltrexone 49 trodusquemine 49 PRECiSE 49 Scale PANSS 49 Major Adverse Cardiac 49 lintuzumab 49 mg TID 49 partial remissions 49 ascending dose 49 Efficacy endpoints 49 dosing regimen 49 serum uric acid sUA 49 double blinded randomized 49 confirmatory clinical 49 ELND# 49 fallopian tube cancers 49 ruxolitinib 49 HbA1C levels 49 TAXUS VI 49 tolevamer 49 trough FEV1 49 PROMACTA 49 postintervention 49 ILLUMINATE 49 CRx 49 CK # plasma concentrations 49 pharmacodynamics 49 median PFS 49 tasimelteon 49 mg/# hr 49 Events MACE 49 ULORIC 49 Kaplan Meier analysis 49 XL# XL# XL# XL# 49 Score DAS# 49 ADAGIO study 49 fasting plasma glucose FPG 49 DAS# [002] 49 Phase Ib II 49 HZT 49 peginterferon alfa 2a #KD 49 recurrent GBM 49 methotrexate monotherapy 49 REMICADE ® 49 T#I [002] 49 death reinfarction 49 BARI 2D 49 placebo p = 49 exploratory endpoints 49 multicenter randomized double 49 Tekamlo 49 null responder HCV 49 plasma uric acid 49 GATTEX 49 cannabinor 49 metastatic HRPC 49 peginterferon alfa 2a 49 NP2 Enkephalin 49 hyperphenylalaninemia HPA due 49 Phase 1b trial 49 sunitinib 49 Phase 1b clinical 49 Cimzia TM 49 ponatinib 49 Hyphanox 49 satraplatin Phase 49 sitagliptin 49 rosuvastatin 49 plus gemcitabine 49 virus HCV protease inhibitor 49 pexelizumab 49 dosing 49 glycated hemoglobin levels 49 KRAS status 49 HAMD 49 IPSS 49 8mg/kg 49 eliglustat tartrate 49 Elagolix 49 DAVANAT 49 neratinib 49 SIMPADICO trial 49 corticosteroid dose 49 Timed Walk 49 pharmacodynamics PD 49 β blockers 49 blood Phe 49 romiplostim 49 REYATAZ r arm 49 CLARITY study 49 MYDICAR 49 EVIZON 49 valacyclovir 49 DLTs 49 log# reduction 49 everolimus eluting stents 49 INC# 49 tipranavir r 49 PRT# 49 abiraterone acetate 49 pegylated interferon peg IFN 49 pegylated interferon 49 NEVO RES 49 blind randomized 49 Arikace 49 HIV RNA 49 definite stent thrombosis 49 TAXUS IV 49 inflammatory lesions 49 CDAI 49 antitumor activity 49 Pharmacokinetics PK 49 urinary N telopeptide 49 fondaparinux 49 GetGoal Phase III 49 chemoradiation therapy 49 OMNARIS HFA 49 PREZISTA rtv 49 paclitaxel eluting stents 49 μg kg 49 dapagliflozin plus 49 rizatriptan 49 HCV RNA 49 Baseline characteristics 49 intermittent dosing 49 PEG IFN 49 FOLFOX6 49 multicenter randomized controlled 49 copies mL 49 pramipexole 49 EXPAREL TM 49 dacetuzumab 49 symptom severity 49 ADCS ADL 49 creatinine clearance 49 SABCS 49 ADVANCE PD 49 gemcitabine carboplatin 49 Phase III randomized 49 CALGB # [001] 49 Retisert TM 49 sirolimus eluting stents 49 blind randomized placebo 49 plasma pharmacokinetics 49 mapatumumab 49 viral suppression 49 pharmacokinetics 49 pegylated interferon alfa 2b 49 AVE# 49 Phase 1a 49 antipsychotic efficacy 49 ocrelizumab 49 #mg dose [003] 49 Fibrin Pad 49 dosing schedules 49 receiving golimumab 49 ipsilateral stroke 49 PegIFN RBV 49 Xanafide 49 blinded placebo controlled 49 favorable pharmacokinetic profile 49 HAQ DI 49 Pivotal Phase 49 postmenopausal osteoporotic women 49 ARIXTRA 49 confirmed CCyR 49 bifeprunox 49 cangrelor 49 CAMMS# 49 telaprevir dosed 49 LY# [003] 49 ELACYT 49 ADAS Cog 49 CDAI score 49 PARTNER Trial 49 Empatic 49 Phase 1a clinical 49 Elitek 49 linaclotide 49 endpoint 49 Phase III 49 CHAMPION PCI 49 Locteron 49 oral ibandronate 49 daily Infergen 49 NEVO ™ 49 dose escalation 49 Chemophase 49 Dextofisopam 49 CRESTOR #mg 49 ACR Pedi 49 Phase IIIb 48 Tolvaptan 48 oral diclofenac 48 CUSTOM III 48 bupropion SR 48 bortezomib 48 serum phosphorus 48 OPAXIO 48 specific antigen PSA 48 IBS C 48 infliximab 48 SWOG 48 pharmacokinetic equivalence 48 HGS ETR2 48 SUCCEED trial 48 achieved sustained virologic 48 subcutaneously administered 48 SSRI citalopram 48 Octreolin 48 clodronate 48 LibiGel Phase III 48 Fludara 48 ONTARGET 48 serum phosphorous 48 mGluR5 NAM 48 selective modulator 48 #mg/m# [001] 48 reinfarction 48 AVADO 48 post hoc 48 tolterodine ER 48 cabazitaxel 48 Cloretazine 48 Rheumatology ACR 48 Randomized Phase 48 Peg IFN 48 ADCS CGIC 48 #mg dose [001] 48 interferon alfa 48 Exelixis compounds 48 insulin glargine 48 motesanib 48 O PPDS 48 Bezielle 48 MAGE A3 ASCI 48 PRECISE 48 paricalcitol 48 serum urate 48 tasocitinib 48 octreotide 48 OADs 48 Fidaxomicin 48 HCV genotype 1 48 PROTECT II 48 CARE HF 48 dose cohort 48 Ophena TM 48 mg BID dose 48 oral olanzapine 48 ADX# 48 Phase IIb III 48 intravascular hemolysis 48 TDF FTC 48 FDA defined valvulopathy 48 Free Survival PFS 48 nasal symptom 48 splenectomized patients 48 azacitidine 48 IRLS 48 Acute Ischemic Stroke 48 antihypertensive agents 48 coadministration 48 Darusentan 48 TMC# [001] 48 evaluating tivozanib 48 RAPAFLO R 48 RE LY 48 multicenter randomized 48 Rezular 48 Gabapentin GR 48 severe exacerbations 48 alfa 2a 48 HbA 1c 48 hemoglobin A1c levels 48 XGEVA 48 darunavir ritonavir 48 tenofovir emtricitabine 48 aprepitant 48 prospective multicentre 48 RAPTIVA 48 Amrubicin 48 Panzem R NCD 48 response CCyR 48 placebo controlled dose escalation 48 icatibant 48 HIV HCV coinfected 48 NEBIDO 48 lanthanum carbonate 48 PEGPH# 48 infarct size 48 6R BH4 48 AXIRON ™ 48 Dual Opioid 48 esomeprazole 48 CorVue ™ 48 zolmitriptan 48 nasopharyngitis 48 annualized relapse 48 randomized blinded 48 mitoxantrone plus 48 fluvastatin 48 substudy 48 avanafil 48 estramustine 48 aromatase inhibitor therapy 48 Atacand 48 EDEMA4 trial 48 Viread Emtriva 48 Phase III trials 48 MoxDuo IR 48 AZD# 48 IFN alfa 48 AGILECT ® 48 Rivaroxaban 48 Phase #/#a 48 haematologic 48 PIX# [002] 48 oxymorphone ER 48 reslizumab 48 tiotropium 48 Ranolazine 48 bioequivalence 48 NRTI 48 blind placebo 48 aliskiren 48 Sprycel dasatinib 48 Rasilez Tekturna 48 goserelin 48 pioglitazone 48 AIR CF2 48 EOquin 48 RRMS patients 48 FOLFOX 48 randomization 48 baseline LDH 48 prospective multicenter 48 methotrexate MTX 48 #th Annual Interscience 48 plasma concentrations 48 events MACE 48 vasomotor symptoms 48 decitabine 48 statistically significant p = 48 rHuPH# 48 DU #b 48 pharmacodynamic endpoints 48 venlafaxine XR 48 CoreValve System 48 QTcF 48 lispro 48 NAbs 48 AZX# 48 DURATION 48 Clolar ® 48 antihypertensive therapy 48 fosamprenavir 48 levosimendan 48 concomitant medications 48 NGX# 48 Initiated Phase 48 MoxDuo 48 olanzapine Zyprexa 48 Brief Psychiatric 48 Recentin 48 Cimzia ® 48 UPDRS 48 refractory AML 48 vertebral fracture 48 Hb A1C 48 mg d 48 odanacatib 48 standard chemotherapy regimen 48 ENDEAVOR IV 48 Xinlay 48 darusentan 48 JANUVIA 48 graft occlusion 48 STELARA 48 BCIRG 48 certolizumab pegol 48 preclinical efficacy 48 randomized controlled clinical 48 alteplase 48 CombAT 48 dosing intervals 48 Randomized Evaluation 48 TMC# [002] 48 amoxicillin clavulanate 48 micafungin

Back to home page